Market Overview

Novocure Reports Second Quarter 2018 Financial Results and Provides Company Update

Share:

Quarterly net revenues of $61.5 million, representing 60 percent
growth versus the second quarter 2017 and 18 percent growth versus the
first quarter 2018

Submission of local coverage determination reconsideration request to
the durable medical equipment Medicare administrative contractors
following June CMS announcement of new payment rules for durable medical
equipment products

STELLAR data in mesothelioma will be presented at IASLC in late
September

Novocure (NASDAQ:NVCR) today reported financial results for the three
and six months ended June 30, 2018. The company also highlighted
continued commercial momentum for Optune and continued clinical
development progress.

 

Second quarter 2018 highlights include:

     

Three months ended
June 30,

Six months ended
June 30,

2018   2017   % Change 2018   2017   % Change
 
Non-financial
Active patients at period end(1) 2,169 1,460 49% 2,169 1,460 49%
Prescriptions received in period(2) 1,244 1,059 17% 2,502 1,953 28%
 
Financial, in millions
Net revenues $ 61.5 $ 38.4 60% $ 113.6 $ 73.3 55%
Gross profit $ 41.7 $ 25.2 65% $ 75.6 48.4 56%
Net loss $ (15.5 ) $ (21.2 ) 27% $ (36.2 ) $ (39.2 ) 8%
 
Cash and cash equivalents at the end of period $ 114.5 $ 80.2

Short-term investments at the end of period

$ 104.5 $ 104.2
(1)   An "active patient" is a patient who is on Optune under a commercial
prescription order as of the measurement date, including patients
who may be on a temporary break from treatment and who plan to
resume treatment in less than 60 days.
 
(2) A "prescription received" is a commercial order for Optune that is
received from a physician certified to treat patients with Optune
for a patient not previously on Optune. Orders to renew or extend
treatment are not included in this total.
 

"In the second quarter of 2018, Novocure demonstrated continued
commercial momentum for Optune and continued progress on key clinical
development programs," noted Asaf Danziger, Novocure's Chief Executive
Officer. "We delivered record quarterly revenue of $61.5 million, up 60
percent from the second quarter 2017 and 18 percent from the first
quarter 2018. We continued to see steady growth in prescriptions for
patients with newly diagnosed GBM, representing nearly 75% of
prescriptions in the second quarter, which we believe is a sign of
increasing physician confidence and belief in Optune."

"I am pleased to announce Novocure submitted a local coverage
determination reconsideration request to the Medicare DME MACs on June
20. Our decision to file for coverage followed a CMS announcement of new
payment rules for DME products earlier in June," said William Doyle,
Novocure's Executive Chairman. "We believe the new CMS payment rules
reflect the meaningful progress made during our multi-year dialogue with
the agency and provide us with a path forward to secure Medicare
coverage and payment for Optune."

"Our STELLAR phase 2 pilot trial data in mesothelioma were accepted for
presentation at the upcoming IASLC meeting in late September. Looking
ahead, we are on track to start our sixth phase 3 pivotal trial, the
INNOVATE 3 trial in recurrent ovarian cancer, later this year and just
opened our phase 2 pilot HEPANOVA trial in advanced liver cancer,"
continued Mr. Doyle. "Novocure is a global oncology company with a
proprietary platform technology offering both a growing commercial
business today and significant potential for future expansion into new
indications. We believe our progress in the second quarter illustrates
our ongoing commitment to execution."

Second quarter 2018 operating statistics and financial update

There were 2,169 active patients on Optune at June 30, 2018,
representing 49 percent growth versus June 30, 2017, and 8 percent
growth versus March 31, 2018. Increased adoption drove the increase in
active patients with steady growth in prescriptions for patients with
newly diagnosed GBM, who typically have a longer duration of treatment
with Optune, and year-over-year prescription growth.

  • In the United States, there were 1,575 active patients on Optune at
    June 30, 2018, representing 45 percent growth versus June 30, 2017.
  • In Germany and other EMEA markets, there were 557 active patients on
    Optune at June 30, 2018, representing 48 percent growth versus June
    30, 2017.
  • In Japan, there were 37 active patients on Optune at June 30, 2018,
    representing 3,600 percent growth versus June 30, 2017.

Additionally, 1,244 prescriptions were received in the three months
ended June 30, 2018, representing 17 percent growth compared to the same
period in 2017, and a 1 percent decline versus the three months ended
March 31, 2018. The year-over-year increase in prescriptions was driven
primarily by commercial activities in the United States and Germany and
initial launch efforts in Japan. We saw steady growth in prescriptions
for newly diagnosed GBM with more than 900 Optune prescriptions, nearly
75% of the total, written for patients with newly diagnosed GBM.

  • In the United States, 947 prescriptions were received in the three
    months ended June 30, 2018, representing 18 percent growth compared to
    the same period in 2017.
  • In Germany and other EMEA markets, 265 prescriptions were received in
    the three months ended June 30, 2018, representing 4 percent growth
    compared to the same period in 2017.
  • In Japan, 32 prescriptions were received in the three months ended
    June 30, 2018, representing 3,100 percent growth compared to the same
    period in 2017.

For the three months ended June 30, 2018, net revenues were $61.5
million, representing 60 percent growth versus the same period in 2017.
Revenue growth was driven by increased Optune adoption in the United
States and Germany, initial launch efforts in Japan and by a decrease in
the gross-to-net revenue spread

For the three months ended June 30, 2018, cost of revenues was $19.8
million compared to $13.2 million for the same period in 2017,
representing an increase of 51 percent. The increase was primarily
driven by the cost of shipping transducer arrays to a higher volume of
commercial patients, as well as an increase in field equipment
depreciation.

Research, development and clinical trials expenses for the three months
ended June 30, 2018, were $11.4 million compared to $9.4 million for the
same period in 2017, representing an increase of 21 percent. This was
primarily due to an increase in clinical trial and personnel expenses
for our LUNAR, METIS, and PANOVA trials and an increase in costs
associated with regulatory affairs.

Sales and marketing expenses for the three months ended June 30, 2018,
were $19.2 million compared to $16.4 million for the same period in
2017, representing an increase of 17 percent. This was primarily due to
increased marketing and market access expenses, increased personnel and
facility expenses to support our geographical expansion in Japan and
Austria and an increase in share-based compensation.

General and administrative expenses for the three months ended June 30,
2018, were $18.2 million compared to $15.0 million for the same period
in 2017, representing an increase of 21 percent. This was primarily due
to an increase in non-cash share-based compensation and an increase in
professional services.

Personnel costs for the three months ended June 30, 2018, included $10.2
million in non-cash share-based compensation expenses, comprised of $0.3
million in cost of revenues; $1.3 million in research, development and
clinical trials; $1.9 million in sales and marketing; and $6.8 million
in general and administrative expenses. Total non-cash share-based
compensation expenses for the second quarter 2017 were $7.6 million.

Net loss for the three months ended June 30, 2018, was $15.5 million
compared to net loss of $21.2 million for the same period in 2017,
representing a 27 percent improvement in net income.

At June 30, 2018, we had $114.5 million in cash and cash equivalents and
$104.5 million in short-term investments, for a total balance of $219.0
million in cash, cash equivalents and short-term investments. This
represents an increase of $2.6 million in cash and investments since
March 31, 2018.

Anticipated clinical trial milestones

  • Phase 2 pilot STELLAR trial in mesothelioma data presentation (2H 2018)
  • First patient enrollment in phase 2 pilot HEPANOVA trial in advanced
    liver cancer (2H 2018)
  • Initiation of phase 3 pivotal trial in recurrent ovarian cancer (2H
    2018)
  • Data collection from phase 3 pivotal METIS trial in brain metastases
    (2020)
  • Data collection from phase 3 pivotal LUNAR trial in non-small cell
    lung cancer (2021)
  • Data collection from phase 3 pivotal PANOVA 3 trial in locally
    advanced pancreatic cancer (2022)

Conference call details

Novocure will host a conference call and webcast
to discuss second quarter 2018 financial results today, Thursday, July
26, 2018, at 8 a.m. EDT. Analysts and investors can participate in the
conference call by dialing 855-442-6895 for domestic callers and
509-960-9037 for international callers, using the conference ID 6554507.

The webcast, earnings slides presented during the webcast and the
corporate presentation can be accessed live from the Investor Relations
page of Novocure's website, www.novocure.com/investor-relations,
and will be available for at least 14 days following the call.

About Novocure

Novocure is a global oncology company developing a proprietary platform
technology called Tumor Treating Fields, the use of electric fields
tuned to specific frequencies to disrupt solid tumor cancer cell
division. Novocure's commercialized product is approved for the
treatment of adult patients with glioblastoma. Novocure has ongoing or
completed clinical trials investigating Tumor Treating Fields in brain
metastases, non-small cell lung cancer, pancreatic cancer, ovarian
cancer and mesothelioma.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania and New York City. Additionally, the
company has offices in Germany, Switzerland, Japan and Israel. For
additional information about the company, please visit www.novocure.com
or follow us at www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure's current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, clinical trial progress,
development of potential products, interpretation of clinical results,
prospects for regulatory approval, manufacturing development and
capabilities, market prospects for its products, coverage, collections
from third-party payers and other statements regarding matters that are
not historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as "anticipate,"
"estimate," "expect," "project," "intend," "plan," "believe" or other
words and terms of similar meaning. Novocure's performance and financial
results could differ materially from those reflected in these
forward-looking statements due to general financial, economic,
regulatory and political conditions as well as more specific risks and
uncertainties facing Novocure such as those set forth in its Annual
Report on Form 10-K filed on February 22, 2018, with the U.S. Securities
and Exchange Commission. Given these risks and uncertainties, any or all
of these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or forward-looking
statements. Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof. The
Private Securities Litigation Reform Act of 1995 permits this discussion.

 
Consolidated Statements of Operations

USD in thousands (except share and per share data)

 
  Three months ended June 30,   Six months ended June 30,  

Year ended
December 31,

2018   2017 2018   2017 2017
Unaudited Unaudited Audited
Net revenues $ 61,514 $ 38,376 $ 113,639 $ 73,256 $ 177,026
Cost of revenues   19,833   13,152   38,071   24,816   55,609
 
Gross profit   41,681   25,224   75,568   48,440   121,417
 
Operating costs and expenses:
Research, development and clinical trials 11,362 9,371 22,466 18,782 38,103
Sales and marketing 19,196 16,360 37,331 31,116 63,528
General and administrative   18,208   15,023   35,533   27,445   59,114
 
Total operating costs and expenses   48,766   40,754   95,330   77,343   160,745
 
Operating loss (7,085 ) (15,530 ) (19,762 ) (28,903 ) (39,328 )
Financial expenses, net   2,860   2,183   7,713   4,629   9,169
 
Loss before income taxes (9,945 ) (17,713 ) (27,475 ) (33,532 ) (48,497 )
Income taxes   5,565   3,461   8,759   5,687   13,165
 
Net loss $ (15,510 ) $ (21,174 ) $ (36,234 ) $ (39,219 ) $ (61,662 )
 
Basic and diluted net loss per ordinary share $ (0.17 ) $ (0.24 ) $ (0.40 ) $ (0.45 ) $ (0.70 )
 

Weighted average number of ordinary shares used in
computing
basic and diluted net loss per share

  91,331,862   88,218,868   90,658,735   87,835,926   88,546,719
 
 
Consolidated Balance Sheets

USD in thousands (except share data)

     
June 30, December 31,
2018 2017
Unaudited Audited
ASSETS
 
CURRENT ASSETS:
Cash and cash equivalents $ 114,456 $ 78,592
Short-term investments 104,499 104,719
Restricted cash 2,169 2,126
Trade receivables 37,643 29,567
Receivables and prepaid expenses 11,216 8,105
Inventories   19,906   22,025
Total current assets   289,889   245,134
 
LONG-TERM ASSETS:
Property and equipment, net 8,891 9,031
Field equipment, net 8,108 9,036
Severance pay fund 111 111
Other long-term assets   2,877   1,986
Total long-term assets   19,987   20,164
 
TOTAL ASSETS $ 309,876 $ 265,298
 
   
June 30, December 31,
2018 2017
Unaudited Audited
LIABILITIES AND SHAREHOLDERS' EQUITY
 
CURRENT LIABILITIES:
Trade payables $ 20,434 $ 17,206
Other payables and accrued expenses   24,813   32,996
Total current liabilities   45,247   50,202
 
LONG-TERM LIABILITIES:
Long-term loan, net of discount and issuance costs 149,195 97,342
Employee benefit liabilities 2,473 2,453
Other long-term liabilities   880   1,737
Total long-term liabilities   152,548   101,532
 
TOTAL LIABILITIES   197,795   151,734
 
COMMITMENTS AND CONTINGENCIES
 
SHAREHOLDERS' EQUITY:
Share capital -

Ordinary shares no par value, unlimited shares authorized; issued
and outstanding:
92,503,273 shares and 89,478,032 shares at
June 30, 2018 (unaudited) and
December 31, 2017, respectively

- -
Additional paid-in capital 729,684 697,165
Accumulated other comprehensive loss (1,273 ) (1,343 )
Accumulated deficit   (616,330 )   (582,258 )
Total shareholders' equity   112,081   113,564
 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 309,876 $ 265,298
 

View Comments and Join the Discussion!